SEC Comment Letter 0000000000-22-012337 to Achilles Therapeutics plc (ACHL) (CIK 0001830749)
Achilles Therapeutics plc (ACHL) (CIK 0001830749)
Date: Nov. 14, 2022 · CIK: 0001830749 · Accession: 0000000000-22-012337
AI Filing Summary & Sentiment
File numbers found in text: 333-268239
Letter
United States securities and exchange commission logo November 14, 2022 Daniel Hood General Counsel Achilles Therapeutics plc 245 Hammersmith Road London W6 8PW Re:Achilles Therapeutics plc Registration Statement on Form F-3 Filed November 8, 2022 File No. 333-268239 Dear Daniel Hood: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Seo Salimi
Show Raw Text
United States securities and exchange commission logo
November 14, 2022
Daniel Hood
General Counsel
Achilles Therapeutics plc
245 Hammersmith Road
London W6 8PW
Re:Achilles Therapeutics plc
Registration Statement on Form F-3
Filed November 8, 2022
File No. 333-268239
Dear Daniel Hood:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Seo Salimi